Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

Novartis today announced that the US Food and Drug Administration (FDA) has approved Itvisma® (onasemnogene abeparvovec-brve) for the treatment of children two years and older, teens, and adults ...

Trump tariffs live updates: White House preps backup plans before Supreme Court verdict as Trump says revenue will 'skyrocket'

Yahoo Finance is chronicling the latest news and updates on President Trump's plans to impose tariffs on goods from other ...